Park Ha Young, Oh In Jae, Kho Bo Gun, Kim Tae Ok, Shin Hong Joon, Park Cheol Kyu, Kwon Yong Soo, Kim Yu Il, Lim Sung Chul, Kim Young Chul, Choi Yoo Duk
Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Tuberc Respir Dis (Seoul). 2019 Jul;82(3):227-233. doi: 10.4046/trd.2018.0070. Epub 2019 Feb 28.
Programmed death-ligand 1 (PD-L1), a transmembrane protein, binds to the programmed death-1 (PD-1) receptor, and anti-PD-1 therapy enables immune responses against tumors. This study aimed to assess clinical characteristics of PD-L1 expression using immunohistochemistry among Korean patients with lung cancer.
We retrospectively reviewed the data of patients with pathologically proven lung cancer from a single institution. PD-L1 expression determined by Tumor Proportion Score (TPS) was detected using 22C3 pharmDx (Agilent Technologies) and SP263 (Ventana Medical Systems) assays.
From July 2016 to July 2017, 267 patients were enrolled. The main histologic type was adenocarcinoma (69.3%). Most participants were smokers (67.4%) and had clinical stage IV disease (60.7%). In total, 116 (42%) and 58 (21%) patients had TPS ≥1% and ≥50%, respectively. The patients were significantly older in TPS ≥1% group than in TPS <1% group (64.83±9.38 years vs. 61.73±10.78 years, p=0.014), not in TPS ≥50% cutoff value (64.69 ± 9.39 vs. 62.36 ± 10.51, p= 0.178). Regarding histologic grade, higher proportions of poorly differentiated tumor were observed in the TPS ≥1% (40.8% vs. 25.8%, p=0.020) and TPS ≥50% groups (53.2% vs. 27.2%, p=0.004). Among 34 patients examined with 22C3 and SP263 assays, 27 had positive results in both assays, with a cutoff of TPS ≥1% (r=0.826; 95% confidence interval, 0.736-0.916).
PD-L1 expression, defined as TPS ≥1%, was related to older age and poorly differentiated histology. There was a similar distribution of PD-L1 expression in both 22C3 and SP263 results.
程序性死亡配体1（PD-L1）是一种跨膜蛋白，可与程序性死亡1（PD-1）受体结合，抗PD-1治疗可引发针对肿瘤的免疫反应。本研究旨在通过免疫组织化学评估韩国肺癌患者中PD-L1表达的临床特征。
我们回顾性分析了来自单一机构的经病理证实的肺癌患者的数据。使用22C3 pharmDx（安捷伦科技公司）和SP263（文塔纳医疗系统公司）检测方法，通过肿瘤比例评分（TPS）来确定PD-L1表达。
2016年7月至2017年7月，共纳入267例患者。主要组织学类型为腺癌（69.3%）。大多数参与者为吸烟者（67.4%），且疾病处于临床IV期（60.7%）。共有116例（42%）和58例（21%）患者的TPS分别≥1%和≥50%。TPS≥1%组患者的年龄显著高于TPS<1%组（64.83±9.38岁 vs. 61.73±10.78岁，p=0.014），而TPS≥50%临界值组则无显著差异（64.69±9.39 vs. 62.36±10.51，p=0.178）。关于组织学分级，TPS≥1%组（40.8% vs. 25.8%，p=0.020）和TPS≥50%组（53.2% vs. 27.2%，p=0.004）中低分化肿瘤的比例更高。在34例同时采用22C3和SP263检测方法的患者中，27例两种检测结果均为阳性，临界值为TPS≥（r=0.826；95%置信区间，0.736-0.916）。
定义为TPS≥1%的PD-L1表达与年龄较大和组织学低分化有关。22C3和SP263检测结果中PD-L1表达的分布相似。
